S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
S&P 500   3,392.44 (+0.66%)
DOW   29,396.30 (+0.56%)
QQQ   237.38 (+1.13%)
AAPL   324.15 (+1.61%)
FB   218.14 (+0.16%)
MSFT   187.47 (+0.13%)
GOOGL   1,530.23 (+0.71%)
CGC   21.90 (-0.18%)
NVDA   312.87 (+5.50%)
BABA   222.97 (+1.11%)
MU   59.99 (+3.88%)
TSLA   920.23 (+7.20%)
AMD   58.93 (+3.59%)
ACB   1.71 (+4.28%)
F   8.01 (-0.62%)
NFLX   387.95 (+0.04%)
PRI   136.27 (+0.48%)
BAC   34.83 (+1.63%)
DIS   141.84 (+1.94%)
GILD   67.43 (+0.61%)
Log in

NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

$25.18
+1.08 (+4.48 %)
(As of 02/19/2020 02:58 PM ET)
Today's Range
$24.06
Now: $25.18
$25.37
50-Day Range
$21.64
MA: $24.07
$27.92
52-Week Range
$9.21
Now: $25.18
$29.67
Volume884,221 shs
Average Volume763,671 shs
Market Capitalization$3.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.78 per share

Profitability

Net Income$-123,580,000.00

Miscellaneous

Employees88
Market Cap$3.18 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its earnings results on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

What price target have analysts set for IOVA?

12 brokerages have issued 1-year price targets for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they expect Iovance Biotherapeutics' stock price to reach $31.73 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

What is the consensus analysts' recommendation for Iovance Biotherapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (2/18/2020)
  • 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
  • 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

Media stories about IOVA stock have been trending very negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of -3.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Iovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 14,830,000 shares, a decrease of 9.5% from the December 31st total of 16,390,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is presently 11.7 days. Currently, 12.8% of the shares of the company are short sold. View Iovance Biotherapeutics' Current Options Chain.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Heron Therapeutics (HRTX), Novavax (NVAX) and Bristol-Myers Squibb (BMY).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.46%), Farallon Capital Management LLC (4.95%), Franklin Resources Inc. (4.34%), State Street Corp (3.43%), Bank of America Corp DE (2.52%) and FMR LLC (2.31%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Franklin Resources Inc., Broadfin Capital LLC, State Street Corp, Rafferty Asset Management LLC, Peregrine Capital Management LLC, Credit Suisse AG and Citigroup Inc.. View Insider Buying and Selling for Iovance Biotherapeutics.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Fairmount Funds Management LLC, Artisan Partners Limited Partnership, Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Crawford Lake Capital Management LLC, Farallon Capital Management LLC and EcoR1 Capital LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $25.30.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $3.19 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  448 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  706
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: What is a stock buyback?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel